Indications - Systemic Autoimmune Disease

We provide actionable insights for patients with systemic autoimmune disease.

Scleroderma or systemic sclerosis (SSc) is a progressive multisystem disease of unknown etiology, marked by cutaneous fibrosis, internal organ fibrosis as well as abnormalities of the immune system and vasculature
It remains a rare disease with ~27.6 cases per 100,000 in the US
While five-year survival has increased from 69% to 84% in the past couple of decades, there is substantial quality-of-life burden, as well as significant mortality and morbidity associated with scleroderma
Current treatments do not significantly alter the course of disease and are directed at symptoms/dysfunctional organs
Current diagnosis focuses on skin characteristics and does not predict disease progression

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that damages tissue in many parts of the body, including skin, joints, lungs, and kidneys
SLE is a leading cause of death for women with 20-150 cases per 100,000 people
The average delay of 6 years between disease onset and proper medical attention/diagnosis is a significant unmet need
Optimal time to treat patients is in the early and active stages of disease, before irreversible damage to tissues
Lack of prognostic biomarkers makes the development of disease-modifying therapies and preventative care extremely difficult
10-15% of Lupus patients will experience premature death due to disease-related complications

If you are interested in ImmuType services and would like additional information.